QQQ   282.04 (-0.64%)
AAPL   142.16 (-0.34%)
MSFT   245.42 (-0.80%)
META   115.90 (+0.49%)
GOOGL   92.83 (-0.94%)
AMZN   89.09 (-1.39%)
TSLA   179.05 (+3.23%)
NVDA   170.01 (-0.98%)
NIO   12.63 (-5.82%)
BABA   91.34 (-3.01%)
AMD   68.59 (-2.67%)
T   19.09 (-0.16%)
MU   54.87 (-0.60%)
CGC   2.87 (-7.12%)
F   13.18 (+0.46%)
GE   81.45 (-2.61%)
DIS   93.38 (+0.90%)
AMC   5.94 (-2.14%)
PYPL   73.57 (-0.88%)
PFE   51.72 (-0.12%)
NFLX   320.01 (+3.14%)
QQQ   282.04 (-0.64%)
AAPL   142.16 (-0.34%)
MSFT   245.42 (-0.80%)
META   115.90 (+0.49%)
GOOGL   92.83 (-0.94%)
AMZN   89.09 (-1.39%)
TSLA   179.05 (+3.23%)
NVDA   170.01 (-0.98%)
NIO   12.63 (-5.82%)
BABA   91.34 (-3.01%)
AMD   68.59 (-2.67%)
T   19.09 (-0.16%)
MU   54.87 (-0.60%)
CGC   2.87 (-7.12%)
F   13.18 (+0.46%)
GE   81.45 (-2.61%)
DIS   93.38 (+0.90%)
AMC   5.94 (-2.14%)
PYPL   73.57 (-0.88%)
PFE   51.72 (-0.12%)
NFLX   320.01 (+3.14%)
QQQ   282.04 (-0.64%)
AAPL   142.16 (-0.34%)
MSFT   245.42 (-0.80%)
META   115.90 (+0.49%)
GOOGL   92.83 (-0.94%)
AMZN   89.09 (-1.39%)
TSLA   179.05 (+3.23%)
NVDA   170.01 (-0.98%)
NIO   12.63 (-5.82%)
BABA   91.34 (-3.01%)
AMD   68.59 (-2.67%)
T   19.09 (-0.16%)
MU   54.87 (-0.60%)
CGC   2.87 (-7.12%)
F   13.18 (+0.46%)
GE   81.45 (-2.61%)
DIS   93.38 (+0.90%)
AMC   5.94 (-2.14%)
PYPL   73.57 (-0.88%)
PFE   51.72 (-0.12%)
NFLX   320.01 (+3.14%)
QQQ   282.04 (-0.64%)
AAPL   142.16 (-0.34%)
MSFT   245.42 (-0.80%)
META   115.90 (+0.49%)
GOOGL   92.83 (-0.94%)
AMZN   89.09 (-1.39%)
TSLA   179.05 (+3.23%)
NVDA   170.01 (-0.98%)
NIO   12.63 (-5.82%)
BABA   91.34 (-3.01%)
AMD   68.59 (-2.67%)
T   19.09 (-0.16%)
MU   54.87 (-0.60%)
CGC   2.87 (-7.12%)
F   13.18 (+0.46%)
GE   81.45 (-2.61%)
DIS   93.38 (+0.90%)
AMC   5.94 (-2.14%)
PYPL   73.57 (-0.88%)
PFE   51.72 (-0.12%)
NFLX   320.01 (+3.14%)
NASDAQ:IRIX

IRIDEX - IRIX Stock Forecast, Price & News

$2.22
+0.05 (+2.30%)
(As of 12/9/2022 12:00 AM ET)
Add
Compare
Today's Range
$2.01
$2.24
50-Day Range
$2.00
$2.63
52-Week Range
$1.96
$6.68
Volume
14,922 shs
Average Volume
36,777 shs
Market Capitalization
$35.49 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$3.00

IRIDEX MarketRank™ Forecast

Analyst Rating
Hold
2.00 Rating Score
Upside/​Downside
35.1% Upside
$3.00 Price Target
Short Interest
Healthy
0.43% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.67mentions of IRIDEX in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.50) to ($0.39) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.98 out of 5 stars

Computer And Technology Sector

423rd out of 621 stocks

Electromedical Equipment Industry

14th out of 23 stocks

IRIX stock logo

About IRIDEX (NASDAQ:IRIX) Stock

IRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology. It offers laser consoles, such as Cyclo G6 laser system for use in the treatment of glaucoma; IQ 532 and IQ 577 laser photocoagulation systems, which are used for the treatment of diabetic macular edema and other retinal diseases; and OcuLight TX, OcuLight SL, OcuLight SLx, OcuLight GL, and OcuLight GLx laser photocoagulation systems that are used to treat proliferative diabetic retinopathy, macular holes, retinal tears, and detachments. The company also provides delivery devices, including TxCell scanning laser delivery system that allows the physician to perform multi-spot pattern scanning; slit lamp adapter, which allows the physician to utilize a standard slit lamp in diagnosis and treatment procedures; and laser indirect ophthalmoscope for use in procedures to treat peripheral retinal disorders. It offers MicroPulse P3 Probe, which is used with its Cylco G6 laser system to perform MicroPulse transscleral laser therapy; G-Probe, which is used in procedures to treat uncontrolled glaucoma; G-Probe and G-Probe Illuminate, which are used in procedures to treat refractory glaucoma; and EndoProbe family of products for use in vitrectomy procedures. The company serves ophthalmologists, research and teaching hospitals, government installations, surgical centers, hospitals, veterinary practices, and office clinics. It markets its products through direct and independent sales force in the United States, as well as through independent distributors internationally. The company was formerly known as IRIS Medical Instruments, Inc. and changed its name to IRIDEX Corporation in November 1995. IRIDEX Corporation was incorporated in 1989 and is headquartered in Mountain View, California.

Receive IRIX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for IRIDEX and its competitors with MarketBeat's FREE daily newsletter.

IRIX Stock News Headlines

StockNews.com Initiates Coverage on IRIDEX (NASDAQ:IRIX)
IRIDEX Third Quarter 2022 Earnings: Beats Expectations
Recap: Iridex Q2 Earnings
See More Headlines
Receive IRIX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for IRIDEX and its competitors with MarketBeat's FREE daily newsletter.

IRIX Company Calendar

Last Earnings
11/11/2021
Today
12/09/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
3/09/2023

Industry, Sector and Symbol

Industry
Electromedical equipment
Sub-Industry
N/A
Current Symbol
NASDAQ:IRIX
Employees
119
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$3.00
High Stock Price Forecast
$3.00
Low Stock Price Forecast
$3.00
Forecasted Upside/Downside
+35.1%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
1 Analysts

Profitability

Net Income
$-5,220,000.00
Pretax Margin
-15.39%

Debt

Sales & Book Value

Annual Sales
$53.90 million
Book Value
$1.47 per share

Miscellaneous

Free Float
15,331,000
Market Cap
$35.49 million
Optionable
Not Optionable
Beta
1.24

Key Executives

  • Mr. David I. Bruce (Age 63)
    Pres, CEO & Director
    Comp: $701.07k
  • Mr. Fuad Ahmad (Age 52)
    Interim Chief Financial Officer
    Comp: $560.4k
  • Mr. Patrick Mercer (Age 50)
    Chief Operating Officer
    Comp: $516.02k
  • Ms. Leigh Salvo
    Head of Investor Relations













IRIX Stock - Frequently Asked Questions

Should I buy or sell IRIDEX stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for IRIDEX in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" IRIX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in IRIX, but not buy additional shares or sell existing shares.
View IRIX analyst ratings
or view top-rated stocks.

What is IRIDEX's stock price forecast for 2023?

1 equities research analysts have issued 12-month target prices for IRIDEX's stock. Their IRIX share price forecasts range from $3.00 to $3.00. On average, they anticipate the company's stock price to reach $3.00 in the next twelve months. This suggests a possible upside of 38.2% from the stock's current price.
View analysts price targets for IRIX
or view top-rated stocks among Wall Street analysts.

How have IRIX shares performed in 2022?

IRIDEX's stock was trading at $6.11 at the beginning of the year. Since then, IRIX shares have decreased by 64.5% and is now trading at $2.17.
View the best growth stocks for 2022 here
.

When is IRIDEX's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 9th 2023.
View our IRIX earnings forecast
.

How were IRIDEX's earnings last quarter?

IRIDEX Co. (NASDAQ:IRIX) released its earnings results on Thursday, November, 11th. The medical equipment provider reported ($0.14) EPS for the quarter, topping the consensus estimate of ($0.15) by $0.01. The medical equipment provider had revenue of $13.26 million for the quarter, compared to analyst estimates of $11.90 million. IRIDEX had a negative net margin of 15.50% and a negative trailing twelve-month return on equity of 43.06%. During the same quarter last year, the business earned ($0.12) earnings per share.

What guidance has IRIDEX issued on next quarter's earnings?

IRIDEX issued an update on its FY 2022 earnings guidance on Thursday, November, 10th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $56.00 million-$58.00 million, compared to the consensus revenue estimate of $57.14 million.

What is Theodore A. Boutacoff's approval rating as IRIDEX's CEO?

7 employees have rated IRIDEX Chief Executive Officer Theodore A. Boutacoff on Glassdoor.com. Theodore A. Boutacoff has an approval rating of 64% among the company's employees.

What other stocks do shareholders of IRIDEX own?
What is IRIDEX's stock symbol?

IRIDEX trades on the NASDAQ under the ticker symbol "IRIX."

Who are IRIDEX's major shareholders?

IRIDEX's stock is owned by many different retail and institutional investors. Top institutional investors include Paragon Associates & Paragon Associates II Joint Venture (5.00%), Renaissance Technologies LLC (2.83%), Dimensional Fund Advisors LP (1.36%) and Perkins Capital Management Inc. (0.25%). Insiders that own company stock include Nandini Devi and Robert Earle Grove.
View institutional ownership trends
.

How do I buy shares of IRIDEX?

Shares of IRIX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is IRIDEX's stock price today?

One share of IRIX stock can currently be purchased for approximately $2.17.

How much money does IRIDEX make?

IRIDEX (NASDAQ:IRIX) has a market capitalization of $34.70 million and generates $53.90 million in revenue each year. The medical equipment provider earns $-5,220,000.00 in net income (profit) each year or ($0.55) on an earnings per share basis.

How many employees does IRIDEX have?

The company employs 119 workers across the globe.

How can I contact IRIDEX?

IRIDEX's mailing address is 1212 Terra Bella Avenue, Mountain View CA, 94043. The official website for the company is www.iridex.com. The medical equipment provider can be reached via phone at (650) 940-4700, via email at investors@iridex.com, or via fax at 650-940-4710.

This page (NASDAQ:IRIX) was last updated on 12/9/2022 by MarketBeat.com Staff